SelectScience
Join Free
NewsDrug Discovery & Development

Graphene Flagship launches task force to combat COVID-19

Graphene Flagship

This aims to make use of its collective and accumulated knowledge of graphene to fight the current pandemic

4 Jun 2020
Diane Li
Assistant Editor

Industry news

The current pandemic caused by COVID-19 brought to light an urgent need to devise new technologies to protect the human body from its immediate environment. Graphene and related materials are promising candidates for the design of a novel generation of surfaces to help deal with the daily challenges posed by COVID-19, as well as similar future diseases.

The Graphene Flagship Management Panel recognised that it is vital for the Graphene Flagship, as one of the largest Europe Science and Technology projects, to make use of all its collective and accumulated knowledge of graphene and related materials to fight the current pandemic – and those that may come in the future. To this end, it has assembled a targeted and multidisciplinary Working Group, comprising companies and researchers from across the consortium. The group’s ultimate objective is to fully exploit the potential of graphene and related materials to contribute to the global front against this unprecedented societal challenge.

The Working Group aims to establish new connections between researchers, propose relevant topics for future funding calls, and initiate discussions with funders and stakeholders, with the ultimate ambition of making the best use of graphene and related materials in fields such as virology, biosensing and many others.

The Leader of the Working Group is Alberto Bianco, Graphene Flagship Work Package Deputy for Health and Environment, and the Deputy Leader is Paolo Samorì, Graphene Flagship Work Package Deputy for Functional Foams and Coatings. The members of the working Group are Andrea Ferrari, Graphene Flagship Science and Technology Officer, Mar García-Hernández, Work Package Leader for Enabling Materials, Amaia Zurutuza, Scientific Director of Graphene Flagship Partner Company Graphenea and Work Package Deputy for Wafer-scale System Integration, Cinzia Spinato, Graphene Flagship Business Developer at Graphene Flagship Partner ICN2, and Anna Helman, Science Officer at the Flagship partner European Science Foundation. The Working Group will also include virology experts Francesco Stellacci, Professor of Supramolecular Nanomaterials and Interfaces at Flagship Partner EFPL, Arben Mercoçi, ICREA Professor at Flagship Partner ICN2 and Member of the Biomedical Technologies Work Package.

  • The Working Group will have a 360-degree approach, covering fundamental to applied solutions. The group will investigate:
  • The inhibition of the virus by graphene and related materials dispersed in solutions
  • Whether graphene and related materials have the same capacity as antivirals as already demonstrated against bacteria
  • How to modify graphene and related materials with antiviral agents
  • How to design chemically tailored materials to either promote viruses’ adhesion and inhibit their biological activity once adsorbed, or repel viruses
  • How to design coated surfaces better able to withstand repeated cleaning cycles
  • How to formulate disinfectant solutions and detergents containing graphene and related materials to clean surfaces
  • How to design disposable masks, aprons and wearable tissues, with higher impermeability to viruses
  • How to develop personal protective equipment technologies able to act as a barrier between the environment and human body
  • How to create smart tissue, embedding by design not only anti-viral characteristics, but also with other functions
  • How to design new chemical, electrochemical and optical sensors with high specificity for early diagnostics, and for portable point-of-care devices
  • The wider challenges posed by global pandemics, such as how graphene and related materials can improve remote working: for example, by improving telecoms and datacoms, or through the development of more efficient batteries for a new green society.

“We are exploring the use of graphene to inhibit the infectivity of viral particles, as well as designing multifunctional graphene conjugates for conductive surface coatings,” explains Alberto Bianco, Leader of the Graphene Flagship’s Coronavirus Working Group. The surface coatings could be effective against the virus in two ways: either by directly repelling the virus, or by promoting its adhesion and destroying it once adsorbed.

Amaia Zurutuza, Member of the Graphene Flagship’s Coronavirus Work Group and Scientific Director of Graphene Flagship industrial partner Graphenea, emphasises the importance of the group’s collaboration with leading EU companies. “Graphenea is supplying graphene for diagnostics and treatment, and we are working on a number of virus-related projects,” she explains.

“Graphene and related materials are promising candidates to develop the next generation of surfaces, to help with the daily challenges posed by the virus. The Graphene Flagship cannot and will not disregard such a major societal challenge,” comments Paolo Samorì, Deputy Leader of the Working Group.

Prof. Andrea. C. Ferrari, Science and Technology Officer of the Graphene Flagship and Chair of its Management Panel, adds: “In such a difficult and unusual time, it has never been more important to work together. The Graphene Flagship has a proven track record of delivering its promises. Many of our partners and associated members, both industrial and academic, are already working to develop new technologies based on graphene and related materials to help with the fight against COVID-19 and future pandemics. This Working Group will create many opportunities for collaborations both within and externally to the Graphene Flagship. We are convinced graphene and related materials have a role to play to help society tackle this challenging problem, and our Working Group will spearhead the Flagship’s joint efforts in this area.”

Want more of the latest science news straight to your inbox? Become a SelectScience member for free today>>

Links

Graphene FlagshipCompany website

Tags

Combinatorial ChemistryCombinatorial chemistry, also known as combichem, is a technique used in drug discovery to create libraries of structurally related compounds. A library is generated by synthesis with a chemical reactor system or by computer-based modeling of compound combinations. When undertaking combinatorial chemistry consider reagents, buffers, resins and standards.Data AnalysisData analysis hardware and software is available to make data processing straight-forward yet powerful. Data software can be used for math and stats, technical graphing and image analysis. In addition, software is available for specific data analysis of electrophoresis, densitometry, ELISA and DNA sequencing.Cellular PathologyCellular Pathology deals with the microscopic analysis of tissue samples and cells. Sample preparation and processing includes fixation, staining, sectioning and slide mounting, using equipment such microtomes and cryostats. In choosing immunohistochemistry and immunocytochemistry kits, consider chromogens, staining method, antibodies, microscopes and imaging.NanotechnologyNanotechnology, or nanotech, is an engineering technique using molecular scale functional systems. Applications of nanotechnology include medicine and medical devices, electronics, air and water purification, food science and energy production.Biopharmaceutical AdvancesBiopharmaceutical advances follow the development of pharmaceuticals derived from biotechnology, also known as biotechnology medicines. Biopharmaceuticals may be produced from cell lines, plants, or microbial cells. Important considerations of biopharmaceutical use include application, cost, production process and purification.Clinical ChemistryBiochemistry (or clinical chemistry) involves the analysis of bodily fluids using chemical tests. Techniques used include HPLC, chromatography, spectroscopy, mass spectrometry, immunochemical, electrophoresis, turbidometric / spectrophotometric assay, MRI and ISE analysis. Tests are often carried out on plasma or serum but urine (urinalysis) and fecal specimens are also processed.Clinical GeneticsMolecular Genetics covers the analysis of hereditary genetic disease and chromosomal abnormalities. Genetics can be analysed using DNA, RNA, and protein microarrays, PCR, RT PCR and DNA sequencing. Genetic equipment includes genetic workstations, thermal cyclers, cooling blocks and electrophoresis products. Diagnostic kits are used for DNA / RNA extraction and purification.Drug DeliveryDrug Delivery refers to dosage form, route of administration, formulations, technologies, and systems for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effect. Drug delivery is often approached via the biopharmaceutical or small molecule drug's formulation, but it may also involve medical devices or drug-device combination products. Considerations include instrumentation, software and services. Development SoftwareComputational techniques used in both the chemistry and biology aspects of drug development, for data acquisition, data analysis, processing and storage. Software is used for analysis of ADME results, toxicology, clinical trials and regulatory processes. RegulatoryPharmaceutical regulations impact on all areas of drug development, manufacture and control and supply. Services are provided from the early stages of drug development and clinical trials through to dossier submission, approval and marketing. Regulatory also includes submission of analytical studies from the pharmaceutical product and safety. Drug DiscoveryDrug discovery is the process of identifying potential new medications, involving stages such as target identification, compound screening, and preclinical development. It relies on cutting-edge technologies like high-throughput screening, artificial intelligence, and molecular modeling to accelerate the identification of drug candidates. Drug discovery plays a pivotal role in developing new therapies for diseases ranging from cancer to rare genetic disorders. Browse our peer-reviewed product directory to find the latest drug discovery technologies, compare options, check customer feedback, and get pricing directly from manufacturers.VirusesViruses are microscopic pathogens that require a host cell to replicate. Understanding their structure, replication cycle, and impact on the immune system is crucial in developing effective treatments, vaccines, and diagnostic methods. Research continues to focus on emerging viral diseases and antiviral drug discovery. Explore solutions for virus research, detection, and treatment in our peer-reviewed product directory; compare products, check customer reviews, and get pricing directly from manufacturers.GrapheneGraphene is a two-dimensional structure that comprises of a hexagonal honeycomb lattice of carbon atoms. Graphene can conduct electricity and heat, is almost transparent and is 100x stronger than steel by weight.CoronavirusCoronaviruses are a large family of viruses that can cause illnesses ranging from the common cold to more severe diseases like COVID-19. Research into the biology, transmission, and treatment of coronaviruses has become a global priority, particularly since the emergence of SARS-CoV-2. Understanding the virus�s structure and behavior is essential for developing vaccines, diagnostics, and antiviral treatments. Explore our peer-reviewed product directory to discover the latest research tools, diagnostic tests, vaccines, and treatments for coronavirus, compare products, read reviews, and receive pricing directly from manufacturers.

Related articles